1. PI3K/Akt/mTOR
  2. Akt
  3. SC79

SC79,一个特异的、能透过血脑屏障的 Akt 激动剂,可激活胞质中 Akt,并抑制 Akt 膜转位。SC79 特异性结合Akt 的PH 结构域。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

SC79 Chemical Structure

SC79 Chemical Structure

CAS No. : 305834-79-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥270
In-stock
5 mg ¥600
In-stock
10 mg ¥950
In-stock
50 mg ¥2820
In-stock
100 mg ¥4200
In-stock
200 mg ¥5700
In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

Customer Review

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 154 篇科研文献

WB
IF
Cell Viability Assay

    SC79 purchased from MCE. Usage Cited in: Environ Pollut. 2023 Feb 17.

    SC79 induces mitochondria dysfunction and apoptosis in the heart of zebrafish embryos (Fig D and E).

    SC79 purchased from MCE. Usage Cited in: Biopolymers. 2023 Mar 28.

    SC79 (2.5 μM; 4, 6, 24 h) significantly increases the expression of p-AKT and p-AKT/AKT while decreases p-ERK expression and the ratio of p-ERK/ERK ratio in T84 cells.

    SC79 purchased from MCE. Usage Cited in: Biopolymers. 2023 Mar 28.

    SC79 (5.0, 7.5, 10 μM; 24 h) significantly induces cell death in T84 cells.

    SC79 purchased from MCE. Usage Cited in: Toxicology. 2019 May 1;419:32-39.  [Abstract]

    HaCaT cells are treated with SC79 at 10 μM for 0, 0.5, 1, and 2 h, following arecoline treatment of 48 h. Proteins are extracted and used for Western blotting for phosphorylated and total Akt, mTOR, 4E-BP1, and cyclin D1. Akt, mTOR, 4E-BP1 and GAPDH are used as the internal control for p-Akt, p-mTOR, p-4E-BP1 and cyclin D1, respectively.

    SC79 purchased from MCE. Usage Cited in: Mol Med Rep. 2019 May;19(5):4091-4100.  [Abstract]

    Western blot analysis demonstrating the protein levels of LC3, p62, AKT, p-AKT, mTOR and p-mTOR following treatment with Aβ1-42, 3-MA, SC79 and SC79 + RAPA for 48 h, and the expression of the AKT/mTOR signaling pathway‑associated proteins of AKT, p-AKT, mTOR and p-mTOR following treatment with Aβ1-42, 3-MA, SC79 and SC79 + RAPA for 48 h.

    SC79 purchased from MCE. Usage Cited in: Acta Biomater. 2018 Nov;81:278-292.  [Abstract]

    PC12 cells are pretreated with 740-YP (30 μM), or SC79 (13.7 μM), or 3BDO (100 μM) for 1 h, and for the duration of GO (50 μg/mL) incubation for 24 h. LC3 turnover is detected by western blotting.

    SC79 purchased from MCE. Usage Cited in: Biomed Pharmacother. 2018 Oct;106:755-762.  [Abstract]

    LTEP-a-2 cells are exposed to SC79 and GSK3β and AKT phosphorylation levels are significantly increased.

    SC79 purchased from MCE. Usage Cited in: Nutrients. 2018 Sep 23;10(10). pii: E1366.  [Abstract]

    Competition tests of SC79, PHT-427, AT7867, and AKT inhibitor VIII with the CGA probe against enriched AKT by CGA-modified functionalized MMs. Bands of AKT are detected by Western blot.

    SC79 purchased from MCE. Usage Cited in: Oncol Rep. 2019 Feb;41(2):811-818.  [Abstract]

    Cells are cultured with and without CAR/SC79 for 24 h, and cell lysates are prepared and analyzed by western blotting to detect the levels of MDM2 and p53Ser15.

    SC79 purchased from MCE. Usage Cited in: Toxicology. 2017 Jul 1;386:72-83  [Abstract]

    Western blot assays and quantitative analysis show that BPDE treatment reduces the expression levels of AKT and eNOS; while simultaneous addition of SC79 significantly increases their expression.

    SC79 purchased from MCE. Usage Cited in: Royal Society of Chemistry. 11th August 2017

    Phillygenin (Phi) modulates phosphorylation of Akt in BEAS-2B cells. BEAS-2B cells are serum-starved overnight and then treated with SC79 and different doses of Phi for 4 h. Thr 308 and Ser 473 phosphorylation of Akt and total Akt are detected by western blot. β-Actin is used as an internal control.

    查看 Akt 亚型特异性产品:

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    SC79, a unique specific and BBB permeable Akt activator, activates Akt in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt[1][2][3].

    体外研究
    (In Vitro)

    SC79 在 Thr308 和 S473 位点增强 Akt 磷酸化[1]
    SC79 (10.96 μM) 诱导 Akt 的细胞溶质磷酸化。SC79 增强血清饥饿细胞和富含血清培养基中生长的细胞中 IGF1 诱导的 Akt 磷酸化[1]
    SC79 降低神经元兴奋性毒性并防止中风诱导的神经元死亡。SC79 抑制 PHAKTM-GFP 质膜转位[1]
    SC79 恢复 BRAT1 敲低细胞的增殖,并减少 MitoSox 阳性细胞线粒体中超氧化物的产生[2]
    SC79 上调 FLIPL/S 表达,从而抑制 caspase-8 激活[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: HeLa cells.
    Concentration: 4 μg/mL (10.96 μM).
    Incubation Time: 30 min.
    Result: Induced cytosolic phosphorylation of Akt.
    体内研究
    (In Vivo)

    SC79 处理,即使在高得多的剂量 (0.4 mg/g) 下,也不会引起小鼠体重、存活率、外观和行为的任何可检测变化[1]
    SC79 (10 mg/kg,ip) 保护 C57BL/6 小鼠免于 fas 诱导的暴发性肝衰竭[4]
    SC79 保护肝细胞免于 TNFα 介导的细胞凋亡和小鼠免于 Gal/LPS 诱导的肝损伤和损伤[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male, age-matched (6- to 8-weekeold) C57BL/6 or BALB/c mice weighing 16 to 18 g[4].
    Dosage: 10 mg/kg.
    Administration: Intraperitoneally at 0.5 hour before the i.p. administration of an agonistic anti-Fas Jo2 antibody at a lethal dose of 0.5 and 0.4 mg/kg for C57BL/6 and BALB/c mice, respectively.
    Result: Treatment of mice with 10 mg/kg of SC79 at 0.5 hour before Jo2 injection increased mouse survival at 12 hours after Jo2 injection from 0% to 35%, and no additional mortality was observed to the end of the 2-month observation period.
    Animal Model: Male, age-matched (6 to 8 weeks old) C57BL/6 mice weighing 16-18 g[5].
    Dosage: 10 mg/kg.
    Administration: Intraperitoneally at 0.5 h before i.p. administration of 400 mg/kg of D-galactosamine (D-Gal) and 60 µg/kg of lipopolysaccharide (LPS) for C57BL/6 mice.
    Result: Gal/LPS challenge there was more bleeding on the liver of the vehicle control-treated mice as compared to that of SC79-treated mice.
    A single dose of SC79 significantly reduced Gal/LPS-mediated liver damage but not an infiltration of inflammatory cells in liver sections.
    分子量

    364.78

    Formula

    C17H17ClN2O5

    CAS 号
    性状

    固体

    颜色

    White to off-white

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years

    *该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    溶解性数据
    In Vitro: 

    DMSO 中的溶解度 : 100 mg/mL (274.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    Ethanol 中的溶解度 : 50 mg/mL (137.07 mM; 超声助溶)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.7414 mL 13.7069 mL 27.4138 mL
    5 mM 0.5483 mL 2.7414 mL 5.4828 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (13.71 mM); 澄清溶液

      此方案可获得 ≥ 5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% EtOH    90% Corn Oil

      Solubility: ≥ 5 mg/mL (13.71 mM); 澄清溶液

      此方案可获得 ≥ 5 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。

      1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中,混合均匀。

    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。

    *该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: ≥98.0%

    参考文献

    SC79 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.7414 mL 13.7069 mL 27.4138 mL 68.5345 mL
    5 mM 0.5483 mL 2.7414 mL 5.4828 mL 13.7069 mL
    10 mM 0.2741 mL 1.3707 mL 2.7414 mL 6.8534 mL
    15 mM 0.1828 mL 0.9138 mL 1.8276 mL 4.5690 mL
    20 mM 0.1371 mL 0.6853 mL 1.3707 mL 3.4267 mL
    25 mM 0.1097 mL 0.5483 mL 1.0966 mL 2.7414 mL
    30 mM 0.0914 mL 0.4569 mL 0.9138 mL 2.2845 mL
    40 mM 0.0685 mL 0.3427 mL 0.6853 mL 1.7134 mL
    50 mM 0.0548 mL 0.2741 mL 0.5483 mL 1.3707 mL
    60 mM 0.0457 mL 0.2284 mL 0.4569 mL 1.1422 mL
    80 mM 0.0343 mL 0.1713 mL 0.3427 mL 0.8567 mL
    100 mM 0.0274 mL 0.1371 mL 0.2741 mL 0.6853 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    SC79
    目录号:
    HY-18749
    需求量: